Development of the Patient- and Observer-Reported PRUCISION Instruments to Assess Pruritus and Sleep Disturbance in Pediatric Patients with Cholestatic Liver Diseases

被引:0
作者
Chad Gwaltney
Stephanie Bean
Meredith Venerus
Lisa Karlsson
Natalie Warholic
Lise Kjems
Patrick Horn
机构
[1] Gwaltney Consulting,Patient
[2] IQVIA,Centered Solutions
[3] IQVIA,Patient
[4] Albireo Pharma,Centered Solutions
[5] Inc.,undefined
来源
Advances in Therapy | 2022年 / 39卷
关键词
Cholestasis; Outcome assessment; Caregivers; Patient-reported outcome measures;
D O I
暂无
中图分类号
学科分类号
摘要
Bile, a greenish liquid that is made in the liver, is released into the gut to help digest food. In cholestatic liver disease (CLD), bile flow is interrupted, and bile can build up in the body. One potential effect of this buildup is pruritus, or itchiness of the skin, which can be so intense that it interferes with daily activities. In this study, interviews were done with doctors, patients, and their caregivers to develop new tools to evaluate the most impactful symptoms of CLD in children. After interviewing five doctors and 36 patients and caregivers, two questionnaires called PRUCISION were developed and refined. During this process, participants were first asked about the frequency, severity, duration, and impact of their or their child’s symptoms; pruritus was identified as the most common and disruptive symptom associated with CLD, even interfering with sleep. Then, the wording of the questionnaires was modified to make them easier to understand, particularly for younger children. The researchers also had patients do a card-sorting task to ensure that they understood the picture-based responses used in the questionnaires. Finally, more details were added to the instructions for caregivers to more clearly define scratching behaviors. In summary, the questionnaires developed in this study include the perspective of the patient or their caregiver and may be useful to see if new treatments can impact the most prominent symptoms and impacts associated with CLD.
引用
收藏
页码:5126 / 5143
页数:17
相关论文
共 200 条
  • [31] Rawat D(2022)Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial Lancet Gastroenterol Hepatol 7 830-1515
  • [32] Alam S(2020)A systematic review of patient-reported outcomes in primary biliary cholangitis and primary sclerosing cholangitis Hepatol Commun 4 1502-95
  • [33] Kremer AE(2020)Newer approaches to the management of pruritus in cholestatic liver disease Curr Hepatol Rep 19 86-514
  • [34] Oude Elferink RP(2013)Pruritus assessment in clinical trials: consensus recommendations from the International Forum for the Study of Itch (IFSI) Special Interest Group Scoring Itch in Clinical Trials Acta Derm Venereol 93 509-1121
  • [35] Beuers U(2011)Patient-Oriented SCORAD (PO-SCORAD): a new self-assessment scale in atopic dermatitis validated in Europe Allergy 66 1114-202
  • [36] Mehl A(2021)Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: phase 2 study Clin Res Hepatol Gastroenterol 45 199-447
  • [37] Bohorquez H(2021)Evaluation of the role of bile acids and serotonin as markers of pruritus in children with chronic cholestatic liver disease Arab J Gastroenterol 22 442-1198
  • [38] Serrano MS(1999)Use of rifampin for severe pruritus in children with chronic cholestasis J Pediatr Gastroenterol Nutr 29 1184-82
  • [39] Galliano G(2018)Placebo-controlled randomized trial of an intestinal bile salt transport inhibitor for pruritus in Alagille syndrome Hepatol Commun 2 69-479
  • [40] Reichman TW(2018)Development of a novel tool to assess the impact of itching in pediatric cholestasis Patient 11 461-undefined